MHRA Peptide Enforcement History

The Medicines and Healthcare products Regulatory Agency is the UK body responsible for ensuring medicines, medical devices, and blood components meet safety, quality, and efficacy standards. Its Criminal Enforcement Unit (CEU) is the operational arm that investigates, disrupts, and prosecutes individuals and organisations involved in the illegal supply of medicines. The CEU works alongside UK Border Force, the National Crime Agency, and local police forces to execute raids, seize shipments, and shut down online platforms selling unlicensed products.

The legal basis for MHRA enforcement action on peptides comes from the Human Medicines Regulations 2012, which require that any product presented as having properties for treating or preventing disease – or any substance administered to restore, correct, or modify a physiological function – must hold a marketing authorisation. Selling, supplying, or advertising such products without authorisation is a criminal offence. Most research peptides fall within this definition when marketed with therapeutic claims.

The MHRA also enforces the Misuse of Drugs Act 1971 (which controls HGH as a Class C substance) and the Psychoactive Substances Act 2016 (which broadly captures substances producing psychoactive effects when consumed). Neither Act explicitly names most research peptides, which is why enforcement typically proceeds under the Human Medicines Regulations.

The bottom line: The MHRA uses medicine-licensing law, not drug-scheduling law, as the primary basis for peptide enforcement – intent and marketing claims determine legality, not a positive or negative compound list.

Date	Event	Scale / Detail
April 2006	Operation Pangea launched	MHRA leads UK participation in first Interpol-coordinated global operation targeting illegal online medicine sales
August 2013	Melanotan crackdown	72 websites shut down in 3 months, 18 adverse event reports covering 74 reactions (stomach, heart, blood, eye disorders)
2021-2022	Scotland enforcement FOI disclosure	63 enforcement cases, 50 seizures (49 unlicensed imports, 1 supply investigation), 2 active falsified-medicine probes
October 2023	Falsified Ozempic pens identified	Counterfeit semaglutide pens found at two UK wholesalers; 369 fake Ozempic pens seized since January 2023
Full Year 2023	Annual seizure total	GBP 30M+ in seized illegal medicines; 12,000+ websites disrupted; 3,000 social media profiles shut down
Full Year 2024	Annual seizure total	17.5 million doses, GBP 40M+ value; weight-loss medicines described as a “very small part” of seizures (Oct 2024)
October 2025	Northampton facility raid	First illicit weight loss manufacturing facility found in UK; 2,000+ unlicensed retatrutide and tirzepatide pens; GBP 250K+ value; GBP 20K cash seized
Dec 2024 – May 2025	Operation Pangea XVII	7.7 million doses, GBP 17.2M; 367 websites/social media removed; GBP 1.4M in criminal profits denied; 152 medicine types seized
January 2026	2025 annual figures announced	Nearly 20 million doses, GBP 45M; 5,000+ GLP-1 products seized; 4.4M ED doses; 9.9M sedative doses; 1,500+ website disruptions
February 2026	Follow-up raids	CEU raids two additional premises linked to organised criminal network manufacturing and selling unlicensed weight loss medicines
March 2026	Operation Pangea XVIII	2.1 million doses, GBP 4.6M in 14 days; UK topped global seizure rankings (2,122,591 doses); majority controlled drugs

The MHRA’s earliest significant peptide-specific enforcement action centred on Melanotan II, a melanocortin receptor agonist marketed as a tanning injection. By August 2013, the agency had received 18 reports detailing 74 separate adverse reactions including stomach problems, heart problems, blood disorders, and eye disorders. The MHRA responded by shutting down 72 websites selling Melanotan to UK customers in a three-month enforcement sprint, with Senior Policy Advisor for Enforcement Lynda Scammell warning publicly that “people should not be fooled that this is a shortcut to getting a tan safely.”

The Melanotan enforcement revealed a complication that continues to affect MHRA peptide operations. Under the Human Medicines Regulations 2012, a product is only classified as a medicine if it meets the statutory definition – meaning medicinal claims must be present. An MHRA Freedom of Information response disclosed that “a tanning product will only be considered a medicine if it is captured by the definition of a medicinal product” and that “injectable tanning products containing melanotan II are not automatically medicines.” Where vendors stripped therapeutic claims and sold Melanotan II without medicinal positioning, the MHRA’s enforcement tools were limited.

The MHRA noted in its FOI response that it had “repeatedly taken action to remove melanotan products so identified from sale for over 10 years.” Melanotan II products continued to circulate in UK gyms, beauty salons, and tanning studios, with BBC investigations in 2025 purchasing samples from multiple locations across northern England.

The bottom line: The Melanotan campaigns demonstrated both the MHRA’s willingness to pursue peptide enforcement and the regulatory limitation that intent – not substance identity – determines whether a product is subject to medicines law.

The global surge in demand for semaglutide and tirzepatide fundamentally changed MHRA enforcement priorities. In October 2023, the agency identified falsified Ozempic pens at two UK wholesalers – meaning counterfeit products had penetrated the legitimate supply chain, not just the grey market. By January 2023, the MHRA had already seized 369 potentially fake Ozempic pens and received Yellow Card reports of adverse reactions from products claiming to contain semaglutide or liraglutide.

GLP-1 products moved from a “very small part” of seizures in October 2024 to a headline enforcement category by January 2026, when the MHRA announced that more than 5,000 GLP-1 products had been seized during 2025. The speed of this escalation reflects both the demand-driven market dynamics and the willingness of criminal networks to manufacture peptide products domestically.

In October 2025, the MHRA and Northamptonshire Police conducted a two-day raid on a premises in Northampton that the agency described as the first illicit weight loss medicine manufacturing facility discovered in the UK. Officers from the CEU seized tens of thousands of empty weight loss pens ready to be filled, raw chemical ingredients, and more than 2,000 unlicensed retatrutide and tirzepatide pens prepared for shipping. The estimated haul value exceeded GBP 250,000. Officers also found GBP 20,000 in cash suspected to be linked to medicines trafficking, and large quantities of pharmaceutical-grade packaging designed to make the products appear legitimate.

Andy Morling, head of the MHRA’s Criminal Enforcement Unit, described the products as “untested, unauthorised and potentially deadly.” Health Secretary Wes Streeting called it “a victory in the fight against the shameless criminals who are putting lives at risk.”

In February 2026, CEU officers conducted follow-up raids on two additional premises as part of the same investigation into an organised criminal network. The fact that retatrutide – a compound still in clinical trials with no approved formulation anywhere in the world – was being manufactured in the UK for illicit distribution signals the extent to which criminal networks have moved beyond counterfeiting approved medicines to producing entirely unapproved investigational compounds.

The bottom line: The Northampton raid proved that UK peptide enforcement is no longer limited to border interceptions and website shutdowns – domestic manufacturing of illicit peptide products is now a reality.

Operation Pangea has been the MHRA’s most consistent enforcement mechanism since its launch in 2006. Coordinated by Interpol and involving approximately 90 countries, it is the world’s largest initiative targeting illegal online medicine sales. The UK has been among the top participating countries by seizure volume in every recent iteration.

Operation	Period	UK Doses Seized	UK Value
Pangea XVI (approx.)	2023	2 million+	~GBP 5M
Pangea XVII	Dec 2024 – May 2025	7.7 million	GBP 17.2M
Pangea XVIII	10-23 March 2026	2.1 million+	GBP 4.6M

Globally, Pangea XVII dismantled 123 criminal groups, seized 50 million doses worth USD 65 million, and arrested 769 suspects. Pangea XVIII saw approximately 5,700 criminal-linked websites, social media pages, channels, and automated bots disrupted worldwide.

The MHRA’s Criminal Enforcement Unit uses a graduated enforcement toolkit that ranges from compliance notices to criminal prosecution. An FOI response covering Scotland between April 2021 and March 2022 disclosed that the CEU undertook enforcement action in 63 cases during that period, taking the form of Compliance Notices regarding breaches of the Human Medicines Regulations 2012. During the same period there were 50 seizures – 49 concerned unlicensed medicine importation and one related to the supply of an unauthorised medicine, which resulted in “advice and a warning.”

This breakdown reveals the MHRA’s preferred enforcement hierarchy. The agency issues compliance notices as a first-line tool, escalates to seizure for border interceptions, and reserves prosecution for organised supply operations. For peptide vendors specifically, the most common enforcement outcome is a compliance notice or website takedown rather than criminal charges – though the Northampton facility raid demonstrates that manufacturing operations face the full weight of criminal investigation.

The Melanotan Classification Problem

A recurring challenge in MHRA peptide enforcement is the statutory definition of “medicinal product.” Under the Human Medicines Regulations, the MHRA must demonstrate that a product is presented as having properties for treating or preventing disease, or that it modifies physiological function, before enforcement action is available. An MHRA FOI response disclosed that “a tanning product will only be considered a medicine if it is captured by the definition of a medicinal product” and that “the definition of a medicine does not allow us to consider mode of administration in isolation.” This means an injectable Melanotan II product sold without therapeutic claims – marketed purely as a “research chemical” – may fall outside the MHRA’s enforcement reach even though it is self-injected by consumers.

This contrasts sharply with the approach taken in Australia, where the TGA uses the Poisons Standard to schedule specific compounds by name – making possession or importation unlawful regardless of how the product is marketed. The UK system’s reliance on intent-based classification gives vendors a potential evasion route that does not exist in scheduling-based jurisdictions.

The MHRA’s enforcement activity extends well beyond physical seizures. The agency has progressively expanded its digital enforcement capability, targeting websites, social media accounts, and online marketplace listings that advertise or sell unlicensed medicines.

In 2023, the MHRA disrupted more than 12,000 websites and shut down almost 3,000 social media profiles. In 2025, the CEU recorded more than 1,500 disruptions to websites and social media accounts marketing illegal products to the public. This represents a shift from volume-based takedowns toward more targeted intelligence-led operations focused on organised criminal networks operating across multiple platforms.

The digital enforcement dimension is particularly relevant for peptide vendors, many of whom operate primarily through social media, messaging apps, and small e-commerce sites rather than through traditional pharmacy or wholesale channels. A vendor selling BPC-157 or TB-500 with therapeutic claims on Instagram or TikTok is as much a target for CEU enforcement action as a bulk importer intercepted at the border.

Metric	Figure
Total doses seized since 2006 (Pangea cumulative)	25 million+
Total value seized since 2006	GBP 84 million+
Doses seized in 2025	~20 million
GLP-1 products seized in 2025	5,000+
Website/social media disruptions in 2025	1,500+
Pangea XVIII global seizure rank (March 2026)	UK ranked 1st worldwide

Shift from Border to Domestic

The Northampton raid and subsequent February 2026 raids signal a new enforcement phase. For years, MHRA peptide enforcement focused on border interceptions and online takedowns. The discovery of domestic manufacturing indicates that criminal networks have responded to increased border scrutiny by moving production onshore – sourcing raw ingredients internationally and filling injection pens in UK-based facilities.

GLP-1 Products as the Primary Vector

The overwhelming consumer demand for semaglutide and tirzepatide has made GLP-1 products the highest-value target for criminal networks, surpassing the traditional dominance of erectile dysfunction and sedative medications. This is directly relevant to the peptide community because GLP-1 enforcement creates infrastructure and intelligence capabilities that extend to non-GLP-1 peptides. A CEU investigation into counterfeit tirzepatide pens, for example, may uncover supply chains that also distribute BPC-157, TB-500, or other research peptides.

Organised Crime Escalation

The MHRA increasingly frames peptide enforcement in organised crime terms rather than regulatory compliance terms. CEU head Andy Morling’s statement that “organised criminal groups are exploiting demand and putting people’s health at serious risk” reflects an enforcement posture that prioritises dismantling networks over issuing compliance notices. The GBP 25 million government investment in weight loss support programmes announced alongside the Northampton raid indicates political will behind sustained enforcement spending.

The MHRA’s enforcement history shows a clear trajectory: escalating seizure volumes, expanding digital enforcement, and a pivot from reactive border operations to proactive intelligence-led investigations. For anyone purchasing research peptides in the UK, the practical implications are: products marketed with therapeutic claims are unlicensed medicines regardless of “research only” labelling; border enforcement has intensified year on year with GBP 45 million in seizures during 2025 alone; and the MHRA is now actively investigating domestic manufacturing networks rather than limiting enforcement to imported products.

The MHRA Annual Report and Accounts 2024-2025, laid in Parliament on 21 July 2025, confirms that criminal enforcement of illegally traded medicines – including peptide products – is a strategic priority, not a peripheral function. The agency’s investment in digital surveillance tools and cross-border intelligence sharing suggests enforcement capacity will continue to grow.

The bottom line: The MHRA’s peptide enforcement has scaled from shutting down 72 Melanotan websites in 2013 to seizing nearly 20 million doses of illegal medicines worth GBP 45 million in 2025, with peptide and GLP-1 products now a primary enforcement target.